ArticleJournal of molecular histology2026
Cell-free MSC secretome therapy ameliorates diabetic testicular injury via antioxidant mechanisms.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetes mellitus is a metabolic disorder characterized by persistent hyperglycaemia that may impair male reproductive function. Mesenchymal stem/stromal cell-derived conditioned medium (MSC-CM) has emerged as a promising cell-free therapeutic approach for diabetes-associated complications. This study investigated the effects of CM obtained from MSCs cultured under normoxic (N-CM) or deferoxamine (DFX)-induced hypoxia-mimetic conditions (DFX-CM) on diabetes-related testicular dysfunction in streptozotocin (STZ)-induced diabetic rats. Diabetes was induced in Sprague Dawley rats using a single intraperitoneal injection of STZ (55 mg/kg). Diabetic rats received intraperitoneal administration of N-CM or DFX-CM for 3 weeks. Serum reproductive hormones were analysed by ELISA. Histological and histomorphometric evaluations were performed using haematoxylin and eosin staining, while ultrastructural alterations were examined by transmission electron microscopy (TEM). Oxidative stress markers and antioxidant enzyme activities were also assessed in testicular tissue. Diabetes reduced serum follicle-stimulating hormone (FSH), gonadotropin-releasing hormone, and luteinizing hormone levels, although only FSH showed a significant decrease. Histological analyses revealed mild impairment of spermatogenesis in diabetic rats without significant morphometric alterations. TEM demonstrated marked ultrastructural abnormalities in diabetic testes, including Sertoli cell degeneration and disrupted spermatogenic cell morphology. Both CM treatments attenuated these alterations, with improved ultrastructural organization observed particularly in Sertoli cells. Diabetes also induced oxidative stress, evidenced by reduced catalase and superoxide dismutase activities and elevated malondialdehyde and H
Indexed as
Identifiers
42446804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.